Cadila Healthcare has got the US health regulator USFDA’s approval for marketing anti-viral generic Acyclovir capsules in the American market.
Cadila Healthcare has said in a regulatory filing that the company has got the final approval from the US Food and Drug Administration (USFDA) to market Acyclovir capsules USP 200 mg.
It further added that the drug will be produced at the company’s formulations manufacturing facility at SEZ, Ahmedabad.
